Bolt Biotherapeutics, Inc. Common Stock
$3.56
$0.21 (+6.43%)
$3.10Day Range$3.62
Key Statistics
Market Cap
$6.86M
Shares Outstanding
1.9M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Feb 5, 2021
Round Lot
100
Locale
US
Trading Data
Day Open
$3.32
Day High
$3.62
Day Low
$3.10
Volume
249.4K
VWAP
$3.36
Prev Close
$3.35
Transactions
--
Acc. Volume
--
About Bolt Biotherapeutics, Inc. Common Stock
Bolt Biotherapeutics Inc is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company is focused on the clinical development of BDC-4182, its claudin 18.2 ISAC. Its other pipeline programs include CEA ISAC program a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5, or CEA; PD-L1 ISAC utilizes a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker; and BDC-3042, its dectin-2 agonist antibody program, developed to repolarize critical cells in the tumor microenvironment known as tumor associated macrophages. It operates in single segment.
PHARMACEUTICAL PREPARATIONSSIC 283423 employees900 CHESAPEAKE DRIVE, REDWOOD CITY, CA, 94063650-665-9295IPO Feb 5, 2021US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001641281
- Composite FIGI
- BBG00N8MY5V9
- Share Class FIGI
- BBG00N8MY5W8
- Ticker Root
- BOLT
- SIC Code
- 2834
About Bolt Biotherapeutics, Inc. Common Stock (BOLT) Stock
Bolt Biotherapeutics, Inc. Common Stock (BOLT) closed the 2026-09-18 session at $3.56, up 6.43% versus the previous close (+0.21). The stock opened at $3.32 and traded between $3.10 and $3.62 during that session. Session trading volume was 249K shares. The volume-weighted average price (VWAP) is $3.36.
Bolt Biotherapeutics Inc is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company is focused on the clinical development of BDC-4182, its claudin 18.2 ISAC. Its other pipeline programs include CEA ISAC program a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5, or CEA; PD-L1 ISAC utilizes a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker; and BDC-3042, its dectin-2 agonist antibody program, developed to repolarize critical cells in the tumor microenvironment known as tumor associated macrophages. It operates in single segment.
Bolt Biotherapeutics, Inc. Common Stock has a market capitalization of $6.9 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. BOLT is listed on the XNAS exchange. The company employs approximately 23 people. Bolt Biotherapeutics, Inc. Common Stock is headquartered in REDWOOD CITY, CA. The recorded listing date is 2021-02-05.
On this page you can find market BOLT stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.